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Abstract
Background: Genetic alterations in pediatric primary brain tumors can be used as diagnostic and prognostic markers
and are the basis for the development of new target therapies that, ideally, would be associated with lower mortality
and morbidity. This study evaluates the incidence and interplay of the presence of BRAF V600E mutation and
chromosomal 9p21 deletions in a series of 100 pediatric gliomas, aiming to determine the role of these alterations in
recurrence and malignant transformation, and to verify if they could be used in the clinical set for stratifying patients
for tailored therapies and surveillance.
Methods: Sanger sequencing was used for the assessment of BRAF mutations at exon 15 and Fluorescent In
Situ Hybridization (FISH) with BAC: RP11–14192 for the detection of 9p21 alterations. Expression levels of the
CDKN2A and MTAP by real-time PCR were evaluated in cases with 9p21 deletions. Statistical analysis of genetic and
clinical data was performed using Graph Pad Prism 5 and SPSS Statistics 24 software.
Results: In our cohort it was observed that 7 /78 (8,9%) of the low-grade tumors recurred and 2 (2,6%) showed
malignant transformation. BRAF V600E mutations were detected in 15 cases. No statistically significant correlations
were found between the presence of BRAF V600E mutation and patient’s morphologic or clinical features. Deletions at
9p21 abrogating the CDKN2A/B and MTAP loci were rare in grade I gliomas (12.2%, p = 0.0178) but frequent in grade IV
gliomas (62.5%, p = 0.0087). Moreover it was found that deletions at these loci were correlated with a shorter overall
survival (p = 0.011) and a shorter progression-free survival (p = 0.016).
Conclusions: It was demonstrated that in these tumors BRAF V600E mutated and that CDKN2A/B MTAP co-deletions
may be used for stratifying patients for a stricter surveillance. The Investigating and defining if glial tumors
with CDKN2A/B and MTAP homozygous loss may be vulnerable to new forms of therapy, namely those affecting the
methionine salvage pathway, was proven to be of importance.
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Background
Tumors of the Central Nervous System (CNS) account
for 20–25% of all pediatric cancer diagnoses in the
developed world, being the most prevalent group of can-
cers in children, after leukemia. Although uncommon,
pediatric brain tumors represent the leading cause of
cancer-related mortality in children and adolescents
aged 20 years and under; and the third leading cause of
cancer-related death in young adults aged 20 to 39
years. In addition to their usual high mortality, CNS
tumors are associated with extensive morbidities such
as pituitary dysfunction, growth hormone deficiency,
epilepsy, vision loss, impaired motor skills, memory
dysfunction, attention and behavioral disorders and
reduced intelligence quotient (IQ). So, about 90% of
survivors are left with long term cognitive and psycho-
social deficits [1].
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Glial and neuro-glial derived tumors are the most fre-
quent CNS tumors in pediatric population [1, 2]. They
form an heterogeneous group of neoplasia which are
categorized by the World Health Organization (WHO)
[2, 3] into various entities based on their cellular, genetic
and clinical characteristics.
In what concerns their clinical features, gliomas are
clustered in two major groups: low-grade gliomas
(LGG) and high-grade gliomas (HGG). LGG comprise:
i) the non-diffuse/non-infiltrative pilocytic astrocy-
toma (PA) categorized as WHO grade I tumor due to
its predominantly favorable outcome, which, depend-
ing on their localization, can be cured by surgery
alone: ii) the diffuse/ infiltrative gliomas which are
associated with a less favorable clinical outcome,
namely, recurrence after initial resection and a higher
probability to malignant transformation. The most
frequent histological entities ascertained to the former
group are: the diffuse astrocytoma grade II, ganglio-
gliomas, the angiocentric gliomas and pleomorphic
xanthoastrocytomas.
Conversely, HGG comprise other histological entities that
invariably recur and show progressive disease after the ini-
tial surgical resection. In the HGG are included all WHO
grade III and IV neoplasms and the most frequent histo-
logic categories are: anaplastic astrocytoma, anaplastic pleo-
morphic xanthoastrocytoma and glioblastoma (GBM).
In pediatric low-grade gliomas, the analysis of the
molecular and genetic mechanisms underlying glioma-
genesis allowed for an understanding of MAPK/ERK
pathway activation as fundamental for their develop-
ment. This occurs at high frequency by activation of the
BRAF oncogene; and in lower frequencies: by MYB and
MYBL1 amplifications and rearrangements, and FGFR1
rearrangements and mutations [4–10].
Two different mechanisms may lead to BRAF activa-
tion in pediatric brain gliomas: chromosomal rear-
rangements and point mutations. The most common
BRAF rearrangement is the one resulting in BRAF/
KIAA1549 fusion protein in which the N-terminus of
the protein encoded by KIAA1549 gene is fused with
the C-terminus of the protein encoded by BRAF gene,
preserving the BRAF kinase domain [10, 11]. BRAF ac-
tivating rearrangements were reported to be present in
70% of the pilocytic astrocytomas, in 15% of other
low-grade gliomas, and have only been punctually
observed in high-grade gliomas [9]. Studies performed
by Hawkins et al. (2011) [12], Horbinski et al. (2010)
[13], and Jones et al. (2008) [14], showed that BRAF
rearrangements were an independent favorable prog-
nostic factor in both supra-tentorial and posterior
fossa low-grade gliomas.
The vast majority (> 90%) of BRAF mutations in
pediatric gliomas are BRAF V600E mutations, a somatic
mutation causing the substitution of the amino acid val-
ine by glutamic acid at residue 600 of exon 15. BRAF
V600E mutations have been described in a wide variety
of lesions: 80% of pleomorphic xanthoastrocytomas 33%
of the gangliogliomas, 23% of the diffuse astrocytomas,
10% of the glioblastomas being more frequent in tumors
located in the cerebral cortex [15]. Only rarely BRAF
V600E mutation occurs in conjunction with a BRAF/
KIAA1549 rearrangement in the same tumor [4].
At variance with BRAF rearrangements, the role of
BRAF V600E mutation in the glioma’s evolution and pa-
tient’s follow-up is far from being fully understood and
some contradictory results are found in literature. Ac-
cordingly, while Horbinski et al. (2012) [13] showed that
in their cohort of pediatric low-grade gliomas, BRAF
V600E mutationended to a worse progression-free sur-
vival when compared to wild-type tumors, Mistry et al.
(2015) [16] showed that this mutation was associated
with a prolonged latency to malignant transformation
and, consequently, with a better overall survival when
compared to wild-type pediatric low-grade gliomas.
Moreover, Korshunov, et al. (2015) [17] described a
subgroup of glioblastomas, exclusive to the pediatric
population, that was characterized by the BRAF V600E
mutation and CDKN2A deletion. Although these tumors
had a better overall survival, they still had a high recur-
rence rate (67%).
The CDKN2A gene is mapped at the chromosome 9p21
region and encodes the p16INK4A and p14ARF proteins.
p16INK4A protein has a key role as negative regulator of the
proliferation of normal cells, controlling the progression
through G1 into the S phase of the cell cycle. According to
Raabe et al. (2011) [18], the worst outcomes associated with
CDKN2A gene deletion could reflect a failure to induce
senescence or an escape from the induced tumor senes-
cence in BRAF driven CDKN2A− tumors.
In order to further understand the interplay be-
tween BRAF V600E mutation and the chromosomal
region abrogating the CDKN2A gene: 9p21, a cohort
of 100 pediatric gliomas was retrospectively analyzed.
Materials and methods
Human tumor samples
Analysis was performed in paraffin embedded material
or fresh tumor samples of patients with pediatric gli-
omas that were referred to the Portuguese Institute of
Oncology (IPOFG-Lisbon, Portugal) from 1992 to 2015
following Patient and Institutional Ethical Board Com-
mittee approval.
In total, 100 pediatric gliomas (PG) were selected for
genetic analysis: 67 grade I gliomas, 11 grade II gliomas,
13 grade III gliomas, and 9 grade IV gliomas. Since the
aim of this study was to investigate the influence of
BRAF V600E mutation and 9p21 gene loss, grade I and
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II lesions were assembled in one group, referred as
Low-Grade Gliomas (LGG) and grade III and IV in an-
other group, referred as High-Grade Gliomas (HGG).
Histological classification was performed and revised
according to WHO (2007) criteria. The patients’ clinical
characteristics (tumor’s location, histologic classification,
WHO grade, patient’s age-ranges and gender) and
outcomes are depicted in Fig. 1 and Additional file 1:
Table S1. In grade I gliomas (referred in Additional file
1: Table S1 as LGG1 to LGG66, and LGG82): 32 cases
were females and 35 were males, the mean age in this
group was of: 9.25 years (range from 5months to 17
years); In grade II gliomas (referred as LGG68; LGG70
to 76; LGG78, 80 and 81 in Additional file 1: Table S1):
6 cases were females, 5 males, the mean age in this
group was: 6.02 years (range from 1 year to 17 years). As
to grade III gliomas (referred in Additional file 1: Table
S1 1 as HGG1–2; HGG5 to 15): 3 were females, 10 were
males and the mean age of this group was: 9.36 years
(range from 9months to 16 years). In grade IV glioma
group of this study (referred in Additional file 1: Table
S1 as HGG3; HGG16 to 23): 2 patients were females
and 7 males, the mean age in this group was 10.44 years
(range from 5 years to 15 years).
In accordance with WHO 2007 criteria, patients were
considered to have a recurrent tumor when exhibiting a
glioma of the same histologic grade after at least 1 year of
remission. They were considered to have a de novo tumor
Fig. 1 Graphical representation of the clinical data and of the genetic alterations observed in the cohort of pediatric gliomas. Abreviations: AB (Grade
IV Astroblastoma), AO (Anaplastic Oligodendroglioma), AOA (Anaplastic Oligoastrocytoma), DA (Diffuse Astrocytoma), DIG (Desmoplastic
Infantile Ganglioglioma), DIPG (Diffuse Intrinsic Pontine Glioma); DNET (Dysembryoplastic Neuroepithelial Tumor), GB (Glioblastoma), GC
(Gangliocytoma), GG (Ganglioglioma), GT (Glioneuronal Tumor) OG (Oligodendroglioma), PMA (Pilomyxoid Astrocytoma), PA (Pilocytic Astrocytoma),
PGT (Papillary Glioneuronal Tumor), SEGA (Subependymal Giant Cell Astrocytoma), TGA (Anaplastic Glioneuronal Tumor), XA (Xanthoastrocytoma), XP
(Pleomorphic Xanthoastrocytoma), AA (Anaplastic Astrocytoma), ND (Not Done). Red squares represent the presence of the genetic alteration
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when exhibiting a glioma of the same grade, with a differ-
ent histological type and at a different localization.
Patients were only considered as having a transformation
of LGG to HGG if they exhibited one of the following fea-
tures: i) consecutive histologic diagnosis of LGG and
HGG as per the WHO 2007 criteria, ii) histological diag-
nosis LGG follow by at least 1 year of stable disease,
followed by clinical and radiological progression to HGG.
Fluorescent in situ hybridization (FISH)
FISH technique was used to identify heterozygous and
homozygous deletions of the 9p21 chromosomal region.
It was performed in interphase nuclei with DNA probes
indirectly labeled. A locus-specific BAC probe (RP11–
14912) directed to the chromosomal location 9p21.3
within chromosome 9–21,909,260 and 22,010,414
(Ensembl Homo sapiens version 86.38 (GRCh38.p7) -
was used to identify the 9p21 chromosomal region. An
enumeration probe for chromosome 9 (pMR9A) was
also used. The 9p21 chromosomal region probe was la-
beled with digoxigenin and the chromosome 9 probe with
biotin using the BioPrimeR DNA Labeling System (Invitro-
gen™,by Thermo Fisher Scientific, USA). These labels were
then detected with specific antibodies: anti-digoxigenin-
fluorescein (Roche Diagnostics, Germany) and streptavidin
combined with cyanine 3 (Cy3) fluorophore (Jackson
ImmunoResearch Laboratories, USA), respectively. FISH
signal evaluation was performed in an AxioImager fluores-
cence microscope linked to aCytoVision® software (Applied
Imaging, UK). Analysis was performed by counting at least
100 cells per slide with intact, non-overlapping nuclei taken
from different, randomly chosen fields of view. Deletion
was defined as more than 40% containing 9p21 probe: cep9
probe ≤0.5.
Sequencing using sanger methodology
In the context of this work, sequencing using Sanger
methodology was used to identify a single point muta-
tion (V600E) in the exon 15 of the BRAF gene. DNA
for gene analysis was extracted by different procedures
according to the material used (fresh material or paraf-
fin embedded material). Target gene amplification was
achieved through polymerase chain reaction (PCR),
using the forward primer 5’TCATAATGCTTGCTCTG
ATAGGA3’ and the reverse primer 5’CCGGTTTTTAA
ATTAGTCACCT3’ at an annealing temperature of 58–
59.5 °C. To sequence samples, an automatic sequencer,
ABI PrismTM 3130 Genetic Analyser (Applied Biosys-
tems), was used. Electrophoretograms were compared
with the reference DNA sequence of the studied gene
to identify the presence or absence of mutations. Refer-
ence DNA sequences were obtained from Ensembl data
base, available at: http://www.ensembl.org/index.html.
Expression studies using quantitative real-time RT-PCR
In cases with 9p21 deletions (detected by FISH) expres-
sion analysis was performed by real-time qPCR, using
commercial TaqMan probes for the CDKN2A (Hs00233
365_m1) and MTAP (Hs00559618_m1) genes (Thermo-
Fisher Scientific, USA). Analysis was performed using
QuantStudio5-Applied Biosystems Real-Time PCR Sys-
tem. ABL1 probes as described by Beillard E et al. [19]
were used as endogenous control for gene expression as-
says. RNA from 3 sample cases (CN1, CN2, and CN3),
defined as non-neoplastic brain lesions by pathology,
were used as calibrator controls. We were not able to
extract RNA with sufficient quality and purity, as
analysed by agarose gel electrophoresis and Nanodrop
spectrophotometry (NanoDrop Technologies,USA),
from all cases with 9p21 loss of this cohort. Total RNA
extraction and single-strand cDNA synthesis could only
be performed for 3 LGG presenting 9p21 heterozygous
loss: LGG64, LGG73 and LGG74 and for 3 HGG (grade
IV) with 9p21 homozygous loss: HGG3, HGG18 and
HGG23. Total RNA was extracted from 30mg of the
tumor specimens using the RNeasy® Mini Kit (Qiagen)
and c-DNA synthesis was performed using the super-
script II kit (Invitrogen, ThermoFisher Scientific). Gene
expression was quantified on QuantStudio5 (Applied
Biosystems, ThermoFisher Scientific, USA). Real-Time
PCR System was performed as per manufactures proto-
col. CDKN2A and MTAP expression were normalized
with to reference gene ABL1 and the fold change relative
to CN1, CN2, CN3 samples was calculated.
Statistical analysis
Statistical analyses were carried out using GraphPad
Prism 5 software (San Diego, USA). The two-tailed Fish-
er’s exact test was used to determine the correlations
between the presence or absence of genetic alterations
and patients’ gender, tumors’ WHO grade, histology and
location. The Mann-Whitney test was used to study the
presence or absence of genetic alterations with patient’s
age. Survival curves were compared using the Log-Rank
(Mantel-Cox) test using the IBM SPSS Statistics 24 Soft-
ware. Differences were considered statistically significant
at p-value < 0.05.
Results
BRAF V600E mutation
In total, 94 pediatric gliomas were analyzed for the
BRAF V600E mutation and 15 were found to harbor this
mutation (Fig. 1 and Additional file 1: Table S1): 9/62
(14,5%) grade I gliomas (6 pilocytic astrocytomas (PA)
and 3 gangliogliomas (GG)); 2/11 (18,2%) grade II
gliomas (1 diffuse astrocytoma (DA) and 1 pleomorphic
xanthoastrocytoma (XP) classified as a grade II lesion);
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2/13 (15,4%) grade III gliomas (1 anaplastic astrocytoma
(AA) and 1 anaplastic XP); and 2/9 (22,2%) grade IV gli-
omas (one astroblastoma and one glioblastoma (GBM)).
The presence of BRAFV600E mutation did not show
any correlation with tumor’s WHO grade, histologic
subtype, patients’ age (p = 0.9299) and patients’ gender
(p = 0.1539). This mutation was not found in tumors lo-
cated in the cerebellum (p = 0.0355).
Regarding the correlation of BRAF V600E mutation
with the overall survival rate of the patients, although
no statistically significant correlation could be observed
(p = 0,375), a trend toward a better overall survival (OS)
was detected (Fig. 2). No statistically significant correl-
ation (p = 0,299) was observed when analyzing progres-
sion free survival (PFS) differences between BRAF wild
type (BRAFwt) and BRAF V600E mutated (BRAFmut)
tumors (Fig. 2).
9p21 chromosomal region deletion
For the 9p21 chromosomal region, 76 gliomas were ana-
lyzed, and its deletion was identified in 16 cases, as
depicted in Fig. 1 and Additional file 1: Table S1. 9p21
chromosomal region deletions were observed in 10/59
(16,9%) LGG (cases LGG: 6, 12, 37, 46, 47, 64, 72 to 74
and 81) in which all deletions were heterozygous. 6/17
(35,3%) HGG (HGG: 3, 9, 18, 19, 21 and 23) presented
9p21 deletions, four of which had a homozygous 9p21
chromosomal region deletion.
Statistical analysis demonstrated that 9p21 chromo-
somal region deletion did not correlate with tumor
Fig. 2 Correlation between BRAF and 9p21 alterations and the clinical outcome - Kaplan-Meier curves. a: Overall Survival (OS) curves of BRAF V600E –
positive tumors v.s. BRAFwt tumors, p = 0.375; b: Progression-Free Survival (PFS) curves of BRAF V600E – positive tumors v.s. BRAFwt tumors, p = 0.299; c:
OS curves of the 9p21 chromosomal region deleted tumors v.s those without 9p21 deletion, p = 0.011; (d) PFS curves of the 9p21 chromosomal region
deleted tumors v.s those without 9p21 deletion, p = 0.016
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location, patients’ age (p = 0.6093) and patients’ gender
(p = 0.7831), but it did correlate with gliomas’ grade.
The 9p21 chromosomal region deletion was rare in
grade I gliomas (12.2%, p = 0.0178) but frequent in
grade IV gliomas (62.5%, p = 0.0087). Moreover, this de-
letion also correlated with the histology categorization
of tumors, a p = 0 .0012 was found between 9p21 loss
and glioblastoma histology.
Furthermore, as depicted in Fig. 2 the 9p21 chromo-
somal region deletion was correlated with a worse over-
all survival rate (p = 0.011). The PFS values of 9p21 loss
group were also significantly (p = 0.016) worse than
those of the group with no deletion at 9p21 as observed
in Fig. 2.
BRAF V600E and 9p21 deletion, in recurrence, progression
and development of secondary HGG
Of the 100 gliomas evaluated in our series during a
23-year period it was observed that in the 78 LGG
group, 7 recurred (8,9%) (LGG 2, 3, 34, 36, 40, 54, 68)
and 2 (2,6%) showed progression to HGG (LGG81 and
LGG82) (Table 1). It must be noted that the develop-
ment of gliomas in the patient identified as LGG68
was very interesting. This patient (ruled out as having
Neurofibromatosis type 1) was diagnosed at the age of
4 with a diffuse astrocytoma of the optical nerve,
which was positive for the BRAF V600E mutation and
presented a recurrence, 3 years later, that also was
positive for BRAF V600E. However, at the age of 5
Table 1 Summary of the genetic findings in glioma cases that recurred, progressed to HGG or presented a de novo tumor
Patient N° /
Condition











1 LGG3 1992 < 3 Hypothalamus/Optic Chiasm Pilocytic
Astrocytoma
Negative Negative Alive, 2015
LGG10 2009 > 8 Hypothalamus/Optic Chiasm Pilocytic
Astrocytoma
Negative Negative
2 LGG68 1995 3–8 Hypothalamus/Optic Chiasm Diffuse Astrocytoma Positive ND Alive, 2015
LGG29 1996 3–8 Cerebral Cortex Pilocytic
Astrocytoma
Negative Negative
LGG5 1999 3–8 Hypothalamus/Optic Chiasm Pilocytic
Astrocytoma
Positive Negative
3 LGG40 2000 3–8 Brainstem Pilocytic
Astrocytoma
Negative ND Alive, 2015
LGG41 2002 3–8 Brainstem Pilocytic
Astrocytoma
Negative ND
4 LGG34 2011 3–8 Diencephalon Pilocytic
Astrocytoma
Negative ND Alive, 2015
LGG48 2013 3–8 Unknown Pilocytic
Astrocytoma
ND ND




HGG9 2009 > 8 Cerebellum Anaplastic
Astrocytoma
Negative Positive
6 LGG54 2009 3–8 Cerebral Cortex Ganglioglioma Positive Negative Alive, 2015
LGG53 2014 > 8 Cerebral Cortex Ganglioglioma Positive Negative
7 LGG2 2013 > 8 Hypothalamus / Optic Chiasm Pilocytic
Astrocytoma
Negative ND Alive, 2015
LGG9 2015 > 8 Hypothalamus / Optic Chiasm Pilocytic
Astrocytoma
Negative ND
8 LGG36 2014 > 8 Dienchephalon Pilocytic
Astrocytoma
Negative ND Alive, 2015
LGG37 2015 > 8 Hippocampus Pilocytic
Astrocytoma
Negative Positive




HGG23 2013 > 8 Cerebral Cortex Glioblastoma Positive Positive
LGG Low-grade Glioma,HGG High-grade glioma, ND Not Done
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(two years before recurrence) he also had a pilocytic
astrocytoma, which developed at the cerebral cortex
that did not present BRAF V600E mutation. These
findings suggest that the cortical and the optical
nerve’s LGG of the patient had different cells of origin.
This tumor was therefore considered as de novo
glioma.
In grade III HGG group, five patients showed progres-
sive disease and died (cases HGG1, 8, 9, 10 and 11), 4
patients were alive (HGG5, 6, 12 and 14) and in 3 cases
follow-up was lost.
As for grade IV HGG group (n = 9) three patients died
(HGG 3, 18, 23) of progressive disease. HGG18 was con-
sidered a secondary HGG. This patient had been diag-
nosed in 1998 at age of 4 with acute lymphoblastic
leukemia type B (ALL-B), received a medullar transplant
and was treated with radiotherapy. He was considered at
remission between 2003 and 2009 but, in 2009 at the
age of 15, he was diagnosed as having a glioblastoma. Of
the other grade IV gliomas of our series, two (HGG15
and 16) were still alive in 2015. Both tumors were classi-
fied as astroblastomas. One, HGG15 had a BRAF V600E
mutation. However, none of them presented a deletion
of 9p21 region. Four cases (HGG19, 20, 21, 22) were lost
for follow-up.
CDKN2A and MTAP expression studies by quantitative
real-time RT-PCR
The expression levels for the CDKN2A and MTAP genes
in both the LGG and HGG are depicted in Additional
file 2: Figure S1 and in Additional file 3. In the LGG
cases expression levels for the CDKN2A gene mRNA
levels were normal or elevated. A similar situation was
observed for the MTAP gene for cases LGG64 and
LGG73. However, in LGG74, identified as pilomyxoid
astrocytoma BRAFwt, MTAP gene levels were slightly
down-regulated. In all HGG, expression levels for both
genes were significantly down-regulated.
Discussion
Incidence and interplay of the presence of BRAF V600E
mutation and 9p21 region deletion was evaluated in a
series of 78 LGG and 22 HGG aiming to determine the
role of these two alterations in recurrence and gliomas’
malignant transformation. There was also interest in
verifying if they could be used in a clinical set for strati-
fying patients for existing target therapies and a tailored
strict surveillance.
As to the incidence rate of BRAF V600E mutation
results corroborated previous data [4, 15, 17], showing
that this mutation occurred in all spectra of glioma
types, although being more frequent in gangliogliomas
and diffuse astrocytomas. Accordingly, we identified
BRAF V600E mutation in 43% of the gangliogliomas, in
33% of the diffuse astrocytomas in 13% of the pilocytic
astrocytomas, but also in one anaplastic astrocytoma
and one glioblastoma.
In our population we observed a recurrence incidence
of 8.9% and a 2,6% incidence of pediatric LGG, which
undergo malignant transformation into HGG.
Statistical evaluation revealed no correlation between
the presence of BRAF V600E and recurrence or progres-
sion in our series.
Mistry, et al. (2015) [16] by analysis of a cohort of 886
patients reported a similar incidence rate of pediatric
LGG transformation to sHGG - 2,9%, but at variance
with our data they showed BRAF V600E mutation to be
associated with prolonged latency periods in pediatric
low-grade gliomas. Our data suggests that tumor pro-
gression is independent of the presence of BRAF V600E
mutation since progression free survival rates were very
similar between the two groups: BRAFwt and BRAFmut.
In our series 9p21 deletion was rare in grade I
(12.2%, p = 0.0178) but frequent in grade IV gliomas
(62.5%, p = 0.0087). Moreover, this deletion also cor-
related with the histologic categorization of tumors,
a p = 0.0012 was found between 9p21 deletion and
glioblastoma histology.
In accordance with previous studies performed by
Horbinski et al. (2012) [13], Mistry et al. (2015) [16]
and Roy et al. (2016) [20] results led to the conclu-
sion that homozygous or heterozygous deletions of
the 9p21 chromosomal region were associated with a
shorter overall survival and with a worse progression-
free survival.
Interestingly, the two pediatric LGG (LGG81 and 82)
that underwent malignant transformation into HGG
(HGG 23 and 9 respectively), both presented a 9p21 re-
gion deletion. One, LGG81, also had a BRAF V600E mu-
tation ab initio and the observed latency period until the
development of the HGG was two years. LGG82 did not
present ab initio a BRAF V600E mutation and had a
much longer latency period until the development of the
HGG (13 years). Although the number of cases is
recognizably small, these findings suggest that in
LGG81, a cooperative interplay might have occurred be-
tween BRAF mutation and 9p21 homozygous loss, which
enhanced malignant transformation.
Several tumor suppressor genes (TSG) are known to be
located at 9p21, namely, the Cyclin Dependent Kinase
Inhibitor’s: CDKN2A and B; the Kelch Like Family Mem-
ber 9 (KLHL9) and the Metylthioadenosine Phosphorilase
(MTAP). The role of all these TSG in gliomas has been
under investigation. Huilard et al. (2012) [21] by perform-
ing functional studies in neural progenitor cell and mouse
models evidenced that homozygous CDKN2A/INK4a-Arf
deletion in BRAF V600E expressing cells was sufficient for
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the formation of tumors with histologic features similar
to the malignant astrocytomas in humans [21]. Mistry
et al. (2015) [16] in an array of comparative genomic
hybridization analysis of 886 pediatric gliomas also-
defined that CDKN2A deletions had a central role in
low-grade glioma malignant transformation. On the
other hand, Roy et al. (2016) [20] in a cohort of 379
adult LGG, conversely observed in their genomic
analysis that CDKN2A inactivation was not associated
with progression. Indeed, by correlating gene expres-
sion with zygosity status, they found that CDKN2A
expression levels were normal or even elevated when
associated at heterozygous gene loss, and proposed rather
that KLHL9 and MTAP would concurrently and in a
context-dependent manner promote tumor aggressiveness.
In this study BAC-RP11–14912 was used for FISH
analysis. This BAC has a 101,115 bps genomic insert that
encompasses not only CDKN2A/B, but also the MTAP-
009 gene segment, which encodes a 112 amino acid
MTAP protein. The detection of losses of this DNA seg-
ment in our cases was indicative that both genes could
be involved in the malignant transformation of pediatric
LGG. By performing expression analysis by qPCR for
both the CDKN2A and MTAP genes in cases referred in
our series as: LGG 64; 73; 74 and HGG 3; 18; 23, it was
evidenced that in the LGG characterized by heterozy-
gous gene losses there was still a “normal” expression of
both genes, but in HGG cases, the homozygous loss was
associated with a significant down-regulation of both
CDKN2A and MTAP genes. The observation that MTAP
is also involved in pediatric gliomas is of foremost
importance since in very recent surveys [22, 23] it was
revealed that MTAP deleted cancers were rendered
therapeutically vulnerable at the methionine salvage
pathway. Accordingly, to Mavrakis et al. (2016) [22] and
Marjon K et al. (2016) [23] deletions at 9p abrogating
the MTAP gene lead to the accumulation of its substrate
5′ methilthioadenosine (MTA) and a metabolic “rewiring”
of the tumor cells, which rendered them specifically sens-
ible to drugs that inhibit the methyltransferase axis
composed by: Methionine Adenosyltransferase II alpha
(MAT2A), Protein Arginine Methyltransferase 5 (PMRT5)
and Rio domain containing protein 1 (RIOK1).
As aforementioned, HGG18 case of our cohort (Table 1)
was diagnosed as a secondary glioblastoma following
medullar transplant and radiotherapy of an ALL-B. Reports
on the genetic analysis of secondary CNS tumors in chil-
dren and their previous ALL are exceedingly rare, and the
driver versus passenger mutations that underlie leukemia
metastasis and the development of secondary tumors are
still to be defined [24–26]. HGG18 was negative for the
presence of BRAF V600E mutation but positive for 9p21
deletion (Table 1). No molecular evaluation for these two
genetic alterations could be retrospectively performed in
the leukemia cells, but the karyotype observed in bone mar-
row blasts at relapse revealed a hiperdiploid karyotype, with
54 chromosomes and a gain of two copies of chromosome
9. Although, it could not be ruled out experimentally that
in this case a specific CDKN2A/B and MTAP deletion or
epigenetic silence of these TSGs were not present ab initio
and at relapse in the leukemia cells of the patient, it is pos-
sible to consider that in the CNS microenvironment, but
not in the medullar microenvironment, CDKN2A/B/MTAP
loss and down-regulation contributed to expansion of the
patients neoplastic clone, therefore reinforcing the view
that chromosomal deletions encompassing these genes are
important for glioma progression.
In summary our data allowed us:
i) To verify that the role of BRAF V600E mutation
is dependent of other co-occurring genetic
alterations, specifically 9p21 deletions that
abrogate both the CDKN2A/B and the MTAP
tumor suppressor genes;
ii) To demonstrate that 9p21 deletions correlated
significantly with poor prognosis indicators and its
detection could be used to stratify patients for a
stricter surveillance;
iii) To underline the relevance of investigating and
defining if glial tumors with CDKN2A/B and
MTAP loss may be vulnerable to new forms of
therapy, namely those affecting the methionine
salvage pathway.
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